Goldman Sachs
BIOL

Goldman Sachs’s Biolase, Inc. BIOL Stock Holding History

Goldman Sachs’s Portfolio BIOL Stock Details BIOL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10
Closed -$15K – 6765
2021
Q3 		$15K Sell
10
-59
-86% -$96.3K ﹤0.01% 6165
2021
Q2 		$120K Buy
69
+28
+68% +$52K ﹤0.01% 5903
2021
Q1 		$87K Buy
+41
New +$101K ﹤0.01% 5868
2018
Q2 		– Sell
-2
Closed -$10K – 6101
2018
Q1 		$10K Hold
2
– – ﹤0.01% 5755
2017
Q4 		$10K Sell
2
-2
-50% -$14.1K ﹤0.01% 6210
2017
Q3 		$28K Hold
4
– – ﹤0.01% 6378
2017
Q2 		$55K Buy
4
+2
+100% +$29.7K ﹤0.01% 6339
2017
Q1 		$36K Hold
2
– – ﹤0.01% 6374
2016
Q4 		$37K Sell
2
-1
-33% -$19.8K ﹤0.01% 6468
2016
Q3 		$61K Hold
3
– – ﹤0.01% 6407
2016
Q2 		$43K Hold
3
– – ﹤0.01% 6475
2016
Q1 		$49K Hold
3
– – ﹤0.01% 6444
2015
Q4 		$29K Sell
3
-1
-25% -$10.9K ﹤0.01% 6757
2015
Q3 		$43K Buy
4
+1
+33% +$18.6K ﹤0.01% 6844
2015
Q2 		$59K Hold
3
– – ﹤0.01% 6825
2015
Q1 		$63K Sell
3
-1
-25% -$28.3K ﹤0.01% 6623
2014
Q4 		$119K Buy
4
+1
+33% +$31.3K ﹤0.01% 6502
2014
Q3 		$94K Hold
3
– – ﹤0.01% 6607
2014
Q2 		$77K Buy
3
+2
+200% +$51.1K ﹤0.01% 6652
2014
Q1 		$25K Buy
+1
New +$34.9K ﹤0.01% 6664

Other funds holding BIOL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Goldman Sachs's BIOL Position: Q4 2021 in Review

Goldman Sachs sold out of Biolase, Inc. (BIOL) in Q4 2021, closing a stake of 10 shares — an estimated $15K sold.

Goldman Sachs first reported a position in BIOL in Q1 2014 and held it in 20 quarters. The position peaked at $120K in Q2 2021. 38 funds tracked by Wall St. Rank hold BIOL as of Q4 2021.

  • Goldman Sachs reported no remaining Biolase, Inc. position as of Q4 2021 after selling out during the quarter.
  • Goldman Sachs sold 10 Biolase, Inc. shares in Q4 2021, an estimated $15K.
  • Goldman Sachs first reported a position in Biolase, Inc. in Q1 2014 and held it in 20 quarters.
  • Goldman Sachs's Biolase, Inc. position peaked at $120K in Q2 2021.
  • 38 funds tracked by Wall St. Rank held Biolase, Inc. as of Q4 2021.

Based on Goldman Sachs's 13F filing for Q4 2021, filed 14 Feb 2022.